Pharma packaging companies commit to supply for COVID-19 fight
Stevanato Group, SCHOTT, and Gerresheimer confirm their readiness to support future COVID-19 vaccine with pharmaceutical containers.
The CEOs of Gerresheimer, Stevanato Group, and SCHOTT have pledged to ensure the ample supply of pharmaceutical containers for any future COVID-19 vaccine and treatment, the pharmaceutical packaging firms said on Tuesday.
The companies have also stated that they will make every effort to support the pharma industry’s priorities for overall medication supply in addition to COVID-19 drugs.
Each of the three companies manufactures billions of type-1 borosilicate glass vials - the most proven and widely available material used to store and deliver vaccines around the world.
According to Dr Frank Heinricht, Chairman of SCHOTT’s Management Board, 50 billion borosilicate glass containers are already deployed each year for a wide variety of vaccines and treatments. That fact, coupled with the significant investments to expand capacity, makes SCHOTT "optimistic" that they can support pharma companies by providing high-quality containers.
Since the outbreak of the coronavirus pandemic, the Stevanato Group has implemented all safety measures to protect its employees and deployed all available assets to secure its supplies to pharma companies.
“To support the mass vaccination campaign and the ramp-up industrialization needs, we invested in increasing the manufacturing capacity of vials from borosilicate glass,” said Franco Stevanato, CEO of the Stevanato Group.
Gerresheimer said it is also investing more to deliver high-quality products with additional capacity. "We are fully prepared to support the global market demand for potential COVID-19 vaccines with our vials and syringes being produced in our large production facilities in the US, Mexico, Europe and Asia“, said Dietmar Siemssen, CEO Gerresheimer AG.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.